Francis K. Buadi

28.8k total citations · 3 hit papers
398 papers, 12.5k citations indexed

About

Francis K. Buadi is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Francis K. Buadi has authored 398 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 281 papers in Hematology, 243 papers in Molecular Biology and 141 papers in Oncology. Recurrent topics in Francis K. Buadi's work include Multiple Myeloma Research and Treatments (250 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (148 papers) and Protein Degradation and Inhibitors (79 papers). Francis K. Buadi is often cited by papers focused on Multiple Myeloma Research and Treatments (250 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (148 papers) and Protein Degradation and Inhibitors (79 papers). Francis K. Buadi collaborates with scholars based in United States, Saudi Arabia and Canada. Francis K. Buadi's co-authors include Angela Dispenzieri, Morie A. Gertz, Shaji Kumar, Martha Q. Lacy, S. Vincent Rajkumar, Suzanne R. Hayman, David Dingli, Robert A. Kyle, Stephen J. Russell and John A. Lust and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Francis K. Buadi

376 papers receiving 12.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival in multiple myeloma and the impact of novel therapies

2007 1.7k citations Shaji Kumar, S. Vincent Rajkumar et al. Blood profile →
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2013 957 citations Shaji Kumar, Angela Dispenzieri et al. Leukemia profile →
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francis K. Buadi United States	57	8.7k	7.8k	4.8k	2.3k	1.2k	398	12.5k
Jerry A. Katzmann United States	54	5.1k 0.6×	5.4k 0.7×	2.6k 0.5×	2.6k 1.1×	861 0.7×	171	10.6k
Ute Hegenbart Germany	51	5.8k 0.7×	4.1k 0.5×	2.1k 0.4×	2.0k 0.9×	1.1k 0.9×	281	9.5k
Joan Bladé Spain	61	9.3k 1.1×	12.1k 1.6×	6.9k 1.4×	2.4k 1.0×	400 0.3×	324	14.8k
Donna Reece Canada	48	4.9k 0.6×	5.2k 0.7×	3.8k 0.8×	1.1k 0.5×	621 0.5×	349	8.2k
A. Keith Stewart United States	57	8.0k 0.9×	7.7k 1.0×	4.6k 1.0×	1.5k 0.7×	363 0.3×	189	11.3k
Xavier Leleu France	53	6.4k 0.7×	6.9k 0.9×	4.4k 0.9×	3.0k 1.3×	391 0.3×	457	11.4k
Raymond Alexanian United States	70	7.1k 0.8×	10.5k 1.3×	6.0k 1.2×	3.2k 1.4×	409 0.3×	226	14.3k
Régis Bataille France	71	8.5k 1.0×	10.0k 1.3×	7.5k 1.6×	2.5k 1.1×	593 0.5×	269	16.9k
Prashant Kapoor United States	40	3.8k 0.4×	4.0k 0.5×	2.3k 0.5×	1.3k 0.6×	434 0.4×	327	6.2k
Jean‐Luc Harousseau France	69	8.8k 1.0×	11.0k 1.4×	7.0k 1.5×	2.6k 1.1×	546 0.5×	319	15.8k

Countries citing papers authored by Francis K. Buadi

Since Specialization

Citations

This map shows the geographic impact of Francis K. Buadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis K. Buadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis K. Buadi more than expected).

Fields of papers citing papers by Francis K. Buadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis K. Buadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis K. Buadi. The network helps show where Francis K. Buadi may publish in the future.

Co-authorship network of co-authors of Francis K. Buadi

This figure shows the co-authorship network connecting the top 25 collaborators of Francis K. Buadi. A scholar is included among the top collaborators of Francis K. Buadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis K. Buadi. Francis K. Buadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abdallah, Nadine, Amanika Kumar, Betsy LaPlant, et al.. (2024). Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Advances. 9(5). 1137–1146. 1 indexed citations

Soekojo, Cinnie Yentia, Susan Geyer, Kristen Whitaker, et al.. (2024). Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma. Blood. 144(Supplement 1). 1880–1880.

Vaxman, Iuliana, Shaji Kumar, Angela Dispenzieri, et al.. (2024). Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM. British Journal of Haematology. 206(2). 607–614. 1 indexed citations

Saleh, Abdullah S. Al, M Hasib Sidiqi, Angela Dispenzieri, et al.. (2022). Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal. 12(4). 59–59. 2 indexed citations

Visram, Alissa, S. Vincent Rajkumar, Prashant Kapoor, et al.. (2021). Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal. 11(11). 186–186. 16 indexed citations

Visram, Alissa, Celine M. Vachon, Linda B. Baughn, et al.. (2021). Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 36(4). 1058–1065. 4 indexed citations

Hwa, Yi L., Martha Q. Lacy, Morie A. Gertz, et al.. (2020). Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal Of Haematology. 106(3). 433–436. 2 indexed citations

Sidana, Surbhi, Eli Muchtar, M Hasib Sidiqi, et al.. (2020). Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology. 95(5). 497–502. 32 indexed citations

Buadi, Francis K., Martha Q. Lacy, Gabriela Pérez, et al.. (2020). Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. Blood. 136(Supplement 1). 34–35. 1 indexed citations

10.

Saleh, Abdullah S. Al, M Hasib Sidiqi, Eli Muchtar, et al.. (2019). Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation. 25(8). 1520–1525. 7 indexed citations

11.

Lonial, Sagar, Susanna Jacobus, Rafaël Fonseca, et al.. (2019). Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of Clinical Oncology. 38(11). 1126–1137. 164 indexed citations

12.

Saleh, Abdullah S. Al, M Hasib Sidiqi, Surbhi Sidana, et al.. (2019). Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology. 94(10). 1066–1071. 13 indexed citations

13.

Sidana, Surbhi, M Hasib Sidiqi, Angela Dispenzieri, et al.. (2019). Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology. 94(9). 1020–1026. 31 indexed citations

14.

Binder, Moritz, S. Vincent Rajkumar, Rhett P. Ketterling, et al.. (2019). Substratification of patients with newly diagnosed standard‐risk multiple myeloma. British Journal of Haematology. 185(2). 254–260. 10 indexed citations

15.

Sidiqi, M Hasib, Francis K. Buadi, Angela Dispenzieri, et al.. (2018). Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 25(3). e108–e111. 17 indexed citations

16.

Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations

17.

Kumar, Shaji, Angela Dispenzieri, Jerry A. Katzmann, et al.. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116(24). 5126–5129. 121 indexed citations

18.

Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations

19.

Gertz, Morie A., Suzanne R. Hayman, & Francis K. Buadi. (2009). Transplantation for IgM Amyloidosis and IgM Myeloma. Clinical Lymphoma & Myeloma. 9(1). 77–79. 8 indexed citations

20.

Kumar, Shaji, David Dingli, Martha Q. Lacy, et al.. (2008). Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology. 83(8). 614–617. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact